GLTO
Galecto·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GLTO
Galecto, Inc.
A clinical stage biotech company focused on novel treatments for fibrosis and cancer
75 State Street, Suite 100, Boston, Massachusetts 02109
--
Galecto, Inc., was incorporated in Delaware in October 2019. The company is a clinical-stage biotechnology company developing novel small molecule therapies designed to target biological processes at the heart of cancer and fibrotic diseases. The company's strategy is to focus on diseases without disease-modifying treatment options and where there is a high degree of unmet medical need. The company is focusing on developing a class of new drugs: small molecule inhibitors of galactose-lectin 3 and lysyl oxidase-like 2, or LOXL 2, which target underlying biology for the treatment of multifactorial diseases such as cancer and fibrotic diseases.
Company Financials
EPS
GLTO has released its 2025 Q3 earnings. EPS was reported at -2.36, versus the expected 0, missing expectations. The chart below visualizes how GLTO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
